NanoBio starts cold sores drug Phase 3 trials
The company expects to recruit around 1700 patients to evaluate the effectiveness of NB-001 at 72 clinical sites. The patient recruitment will be completed in 2012. NanoBio Clinical
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).